Karyopharm Therapeutics (STU:25K0) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:25K0 Karyopharm Therapeutics Inc STU:25K0
60 GF Score
Price €6.15
GF Value €5.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:25K0
60GF Score
Karyopharm Therapeutics Inc STU:25K0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Karyopharm Therapeutics (STU:25K0) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of €6.15 is trading 17.8% above its estimated GF Value™ of €5.22. GuruFocus considers Karyopharm Therapeutics to be Modestly Overvalued.

Key valuation signals for STU:25K0:

  • FFO:
  • GF Value™: €5.22 vs. price of €6.15 (17.8% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the STU:25K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Karyopharm Therapeutics Business Description

Other Exchanges KPTI:USA
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
60GF Score

Get the complete analysis for STU:25K0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.15
Price
€5.22
GF Value